# Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

> **NCT03169231** · PHASE2 · COMPLETED · sponsor: **Longeveron Inc.** · enrollment: 150 (actual)

## Conditions studied

- Aging Frailty

## Interventions

- **BIOLOGICAL:** Longeveron Mesenchymal Stem Cells (LMSCs)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03169231
- **Lead sponsor:** Longeveron Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169231, "Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03169231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*